PSC
MYGN icon

Piper Sandler & Co’s Myriad Genetics MYGN Stock Holding History

Piper Sandler & Co’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-5,500
Closed -$206K – 56
2015
Q3 		$206K Buy
+5,500
New +$195K 0.22% 63

Other funds holding MYGN

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Piper Sandler & Co's MYGN Position: Q4 2015 in Review

Piper Sandler & Co sold out of Myriad Genetics (MYGN) in Q4 2015, closing a stake of 5,500 shares — an estimated $206K sold.

Piper Sandler & Co first reported a position in MYGN in Q3 2015 and held it in 1 quarter. The position peaked at $206K in Q3 2015. 232 funds tracked by Wall St. Rank hold MYGN as of Q4 2015.

  • Piper Sandler & Co reported no remaining Myriad Genetics position as of Q4 2015 after selling out during the quarter.
  • Piper Sandler & Co sold 5,500 Myriad Genetics shares in Q4 2015, an estimated $206K.
  • Piper Sandler & Co first reported a position in Myriad Genetics in Q3 2015 and held it in 1 quarter.
  • Piper Sandler & Co's Myriad Genetics position peaked at $206K in Q3 2015.
  • 232 funds tracked by Wall St. Rank held Myriad Genetics as of Q4 2015.

Based on Piper Sandler & Co's 13F filing for Q4 2015, filed 16 Feb 2016.